# Diabetes Research Hub — Monitor Report
**Date:** 2026-04-08
**Previous report:** 2026-04-07
**Scan source:** hub_monitor.py (ran 2026-04-08 02:05:03)

---

## File System Status

| Metric | Value |
|--------|-------|
| Total files tracked | 684 |
| New files (since yesterday) | 3 |
| Modified files | 27 |
| Removed files | 0 |
| Stale files (>14 days) | 352 |

**New files added:**
- `clinical_trials_snapshot_2026-04-08.json` (507.3 KB)
- `pubmed_recent_snapshot_2026-04-08.json` (98.9 KB)
- `monitor_report_2026-04-07.md` (10.4 KB)

**Key file freshness:**

| File | Last Modified | Status |
|------|--------------|--------|
| clinical_trials_latest.json | 2026-04-08 | ✅ Fresh |
| pubmed_recent_latest.json | 2026-04-08 | ✅ Fresh |
| hub_monitor_report.md | 2026-04-08 | ✅ Fresh |
| literature_gap_report.md | 2026-04-07 | ✅ Fresh |
| literature_gap_data.json | 2026-04-03 | ⚠️ 5 days old |
| Diabetes_Research_Tracker.xlsx | 2026-04-03 | ⚠️ 5 days old |

**Notable:** 352 result files are older than 14 days — many are historical snapshots and paper library entries, which is expected. The core pipeline outputs are all current.

---

## Clinical Trial Changes

**Snapshot comparison:** 2026-04-07 → 2026-04-08

| Metric | Count |
|--------|-------|
| Total trials tracked | 755 |
| New trials | 0 |
| Removed trials | 0 |
| Status changes | 0 |
| New results posted | 0 |

**No changes detected overnight.** The trial landscape is stable day-over-day.

### Key Phase 3 Recruiting Trials (Watchlist)

These are the highest-priority active trials from key organizations:

| NCT ID | Sponsor | Trial | Notes |
|--------|---------|-------|-------|
| NCT04786262 | Vertex Pharmaceuticals | VX-880 Safety/Tolerability/Efficacy in T1D | Stem cell-derived islet therapy — flagship trial |
| NCT06832410 | Vertex Pharmaceuticals | VX-880 Efficacy/Safety/Tolerability in T1D | Second VX-880 Phase 3 cohort |
| NCT07222332 | Eli Lilly | Baricitinib to Preserve Beta Cell Function (Children & Adults) | JAK inhibitor for new-onset T1D |
| NCT07222137 | Eli Lilly | Baricitinib for Delay of Stage 3 T1D in At-Risk Children | Prevention trial — disease modification |
| NCT06971472 | Eli Lilly | Orforglipron in Obesity/Overweight + T2D | Oral GLP-1 — potential blockbuster |
| NCT06993792 | Eli Lilly | Orforglipron Master Protocol (Obesity/Overweight) | Broad obesity indication |
| NCT06739122 | Eli Lilly | Dulaglutide 3.0/4.5 mg Pediatric T2D | Expanded dosing for children |
| NCT07076199 | Novo Nordisk | Insulin Icodec (Weekly Insulin) | Once-weekly basal insulin — now FDA-approved as Awiqli |

### Trial Summary by Status

| Status | Count |
|--------|-------|
| RECRUITING | 261 |
| COMPLETED | 253 |
| NOT_YET_RECRUITING | 128 |
| ACTIVE_NOT_RECRUITING | 108 |
| ENROLLING_BY_INVITATION | 5 |

**Trials with posted results:** 254

---

## PubMed Highlights

**Snapshot comparison:** 2026-04-07 → 2026-04-08
- New papers entering alerts: **16**
- Papers dropping out of 30-day window: **15**
- Total unique papers tracked: **130**

### Cross-Domain Papers (Highest Priority)

These papers span multiple research domains and represent the highest-value items for synthesis:

1. **"Recent Advances in Modeling and Prediction of Blood Glucose in Type 1 Diabetes"** (PMID 41943733)
   Domains: Diabetes AI/ML + Closed Loop AP
   *Bridges computational prediction with automated insulin delivery — directly relevant to Tier 1 area #5 (AI/ML Prediction Models).*

2. **"Beyond Weight: Systems Biology and Precision Medicine Redefine Obesity as a Multidimensional Disease"** (PMID 41944002)
   Domains: Diabetes AI/ML + Diabetes Microbiome
   *Multi-omics systems approach to obesity — relevant to Tier 1 area #1 (Multi-Omics Biomarker Integration) and #7 (Microbiome-Metabolic Pathway Analysis).*

3. **"Antigen-specific immunotherapy with a CD4..."** (PMID 41872174)
   Domains: T1D Stem Cell Cure + T1D Immunotherapy
   *Bridges cell therapy and immune modulation — core T1D cure research.*

4. **"Oral and cardiometabolic health through the lens of biobanks and large-scale epidemiologic research"** (PMID 41907858)
   Domains: T2D Remission + Diabetes Multi-Omics
   *Population-scale biobank analysis relevant to Tier 1 area #6 (Epidemiological Data Analysis).*

### Key Therapy Mentions

| Therapy | Found in Recent Papers? | Notes |
|---------|------------------------|-------|
| Orforglipron | No | No new publications (Phase 3 active — watch for results) |
| Retatrutide | No | No new publications this cycle |
| CagriSema | No | No new publications (FDA filing anticipated 2026) |
| Baricitinib | No direct mention | Lilly trials actively recruiting — publications expected |
| Teplizumab | No new papers | FDA sBLA decision due 2026-04-29 (see Breaking News) |
| Tirzepatide | **Yes** | 2 new papers: MACE benefit analysis (Diabetes Care) + real-world Hokkaido-TZP study |
| Semaglutide | **Yes** | Multiple new papers: anti-atherosclerotic effects, hepatic benefits, weight loss |

### Publication Volume Trends

| Activity Level | Domains |
|---------------|---------|
| HIGH (>100 papers/30d) | Diabetes AI/ML (175), T2D GLP-1 (151), Diabetes Microbiome (144), Diabetes Biomarker (122) |
| ACTIVE (20-65) | Health Equity (65), Multi-Omics (45), T2D Remission (40), Gene Therapy (40), Complications (38), Closed Loop AP (22), T1D Immunotherapy (20) |
| LOW (<20) | T1D Stem Cell (18), Epigenetics (6), Drug Repurpose (5), LADA (4) |

**Notable:** LADA (4 papers) and Drug Repurposing (5 papers) remain severely under-published — consistent with our gap analysis findings showing these as high-value targets.

---

## Gap Analysis Summary

**Last updated:** 2026-04-07 (1 day old — current)
**Validation level:** BRONZE (single analytical source)

### Top 5 Under-Researched Intersections

| Rank | Domain Pair | Gap Score | Joint Pubs | Tier 1 Alignment |
|------|-------------|-----------|------------|-------------------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 | — |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 | — |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 | ✅ Tier 1 #4 (Drug Repurposing Computational Screening) |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 | — |
| 5 | Gene Therapy × LADA | 100.0 | 0 | — |

**Tier 1 alignment highlights:**
- **Islet Transplant × Drug Repurposing** (Gap #3) aligns directly with Tier 1 area #4 (Drug Repurposing Computational Screening). The islet repurposing analysis pipeline (completed 2026-04-03) is already addressing this gap.
- **Drug Repurposing × LADA** (Gap #13, score 100.0) is another high-value target for Tier 1 #4 — LADA-specific repurposing screens don't exist.
- **Health Equity × LADA** (Gap #14, score 100.0) — LADA is massively underdiagnosed in minority populations. Relevant to Tier 1 #6 (Epidemiological Data Analysis).
- Several gap pairs involving **Glucokinase** and **Drug Repurposing** align with ongoing Tier 1 #4 work.

---

## Breaking News (Web Search — Last 7 Days)

### FDA Actions & Regulatory

1. **Teplizumab (Tzield) sBLA — Decision Due April 29, 2026**
   FDA has accepted the supplemental Biologics License Application to expand Tzield approval for Stage 2 T1D in children as young as 1 year. PDUFA date: April 29, 2026. This is 3 weeks away — **high priority to monitor.**

2. **Awiqli (Icodec/Once-Weekly Insulin) — FDA Approved**
   Novo Nordisk's once-weekly basal insulin has been approved for adults with T2D. Launch expected Q2 2026. This is the first weekly insulin — a major milestone for diabetes management.

3. **Oral Semaglutide (Ozempic Tablets) — FDA Approved (Feb 2026)**
   Approved in 1.5 mg, 4 mg, and 9 mg strengths for T2D and CV risk reduction. US availability expected Q2 2026.

4. **Orforglipron (Eli Lilly) — FDA Approval Expected 2026**
   Oral non-peptide GLP-1 receptor agonist. Phase 3 trials actively recruiting (tracked in our system). Potential first-in-class oral GLP-1.

5. **CagriSema (Novo Nordisk) — FDA Filing Anticipated 2026**
   Amylin/GLP-1 combination for T2D. Working toward approval.

### Research Breakthroughs

6. **MUSC Stem Cell + Immune Cell Combo Therapy for T1D**
   Medical University of South Carolina received $1M from Breakthrough T1D for a two-part therapy: lab-made insulin-producing cells + custom-engineered immune cells, aiming to eliminate need for immunosuppressive drugs.

7. **AI for Early T1D Identification**
   ADA highlighted AI tools improving early-stage T1D risk prediction up to a year before clinical diagnosis.

---

## Recommended Actions

### Immediate (This Week)

1. **Monitor Teplizumab sBLA decision** — PDUFA date April 29. Review `teplizumab_sNDA_decision_prep.md` (last updated 2026-04-03) and consider refreshing it with the latest regulatory news.

2. **Review 2 new cross-domain papers:**
   - PMID 41943733: Blood glucose modeling/prediction in T1D (AI/ML + Closed Loop)
   - PMID 41944002: Systems biology redefining obesity (AI/ML + Microbiome)

3. **Update tracker** — `Diabetes_Research_Tracker.xlsx` is 5 days old. Consider updating with current trial counts and new PubMed highlights.

### Short-Term (This Month)

4. **Re-run gap analysis** — `literature_gap_data.json` is 5 days old. Consider refreshing:
   `Run: python project1_literature_gap_analysis.py`

5. **Investigate LADA × Drug Repurposing gap** — Both domains are low-publication (LADA: 541, Drug Repurposing: 570) with zero joint publications. This is a computationally tractable gap aligned with Tier 1 #4.

6. **Track Awiqli launch** — With FDA approval confirmed, monitor for real-world evidence publications and update clinical trial dashboard accordingly.

### Ongoing

7. **Continue daily snapshot pipeline** — All automated scripts are running successfully and producing fresh data.

8. **352 stale files flagged** — Most are historical snapshots (expected). No action needed unless specific older analysis files need refresh.

---

*Generated by Diabetes Research Hub Monitor — 2026-04-08*
*Next automated scan: 2026-04-09*
